Blair MacNeil reports
TILRAY MEDICAL LAUNCHES SLEEP-ORIENTED CBN NIGHT OIL FOR MEDICAL CANNABIS PATIENTS IN CANADA
Tilray Brands Inc.'s medical cannabis brand, Aphria, has launched CBN Night Oil, the brand's first CBN (cannabinol) oil medical product formulated for patients' nighttime use.
Blair MacNeil, president, Tilray Canada, said: "Tilray Medical is committed to providing patients in Canada and around the globe with safe, high-quality cannabinoid-based medicine. We are pleased to add a dedicated night oil to the Aphria medical portfolio and broaden our offering of effective medical cannabis products to patients with a wider range of needs."
CBN, or cannabinol, is derived from THC (tetrahydrocannabinol) and is known to help improve the duration and quality of sleep. Aphria's CBN-dominant oil is carefully formulated with 30-milligram CBN per millilitre and 10 mg THC per mL (in a 50 mL bottle) and is composed of broad-spectrum cannabis distillate. Designed to be used in conjunction with a nighttime routine, Aphria's CBN Night Oil is now available across Canada on the Tilray Medical website.
About Tilray Brands
Tilray Brands is a leading global cannabis lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is changing people's lives for the better -- one person at a time -- by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body and soul and invoke a sense of well-being. Tilray's mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and well-being through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray's unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and alcoholic beverages.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.